The disclosure sent Onconova's (NASDAQ: ONTX) stock price down from $1.01 per share to 30 cents in morning trading. The company's stock closed Monday down 66% at 34 cents per share. The company has been developing IV rigosertib as a treatment for patients at higher risks for developing myelodysplastic syndromes, also known as MDS.
Full Answer
How can I get the latest news and ratings for ontx?
May 21, 2021 · What happened to ONTX stock? However, the massive volatility that we’re seeing in Onconova Therapeutics stock isn't due to clinical trial news. The volatility is …
Who sells Onconova Therapeutics (ontx) stock?
Mar 31, 2022 · Onconova Therapeutics' stock was trading at $5.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ONTX shares have decreased by 74.1% and is now trading at $1.40. View which stocks have been most impacted by COVID-19.
What are tvix and ontx?
Apr 07, 2022 · View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations. Get daily stock ideas top-performing Wall Street analysts.
Will ontx outperform or underperform the S&P 500 over the long term?
Dec 18, 2013 · What: Shares of Onconova Therapeutics ( ONTX -2.44% ), a clinical-stage biopharmaceutical company developing small-molecule drugs to treat cancer, dropped as much as 22% after announcing the...
Why is ONTX stock dropping?
The decrease was primarily related to the Company's focus on its Phase 1 program with narazaciclib, following the completion of the Phase 3 INSPIRE study in 2020. General and administrative expenses were $9.4 million for 2021, compared with $8.3 million for 2020.
Is ONTX a good stock to buy now?
The consensus among 2 Wall Street analysts covering (NASDAQ: ONTX) stock is to Strong Buy ONTX stock.
Will ONTX stock go up?
Stock Price Forecast The 3 analysts offering 12-month price forecasts for Onconova Therapeutics Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 7.00. The median estimate represents a +623.68% increase from the last price of 1.52.
Is ONTX undervalued?
Valuation metrics show that Onconova Therapeutics, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ONTX, demonstrate its potential to underperform the market.
Is ONTX going to reverse split?
Onconova Therapeutics, Inc. (ONTX) will effect a one-for-fifteen (1-15) reverse split of its common stock. The reverse stock split will become effective on Friday, May 21, 2021. In conjunction with the reverse split, the CUSIP number will change to 68232V801.May 20, 2021
Is onconova a buy or sell?
Onconova Therapeutics has received a consensus rating of Buy.
Why is ONTX going up?
The increase was primarily related to costs related to special and annual general meeting expenses in the 2021 period. Ladenburg Thalmann analyst Ahu Demir initiates coverage on Onconova Therapeutics (NASDAQ:ONTX) with a Buy rating and announces Price Target of $7.
Is Onconova Therapeutics a buy right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are curren...
How has Onconova Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?
Onconova Therapeutics' stock was trading at $5.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World He...
Are investors shorting Onconova Therapeutics?
Onconova Therapeutics saw a decrease in short interest in the month of February. As of February 28th, there was short interest totaling 171,900 sha...
When is Onconova Therapeutics' next earnings date?
Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 16th 2022. View our earnings forecast for On...
How were Onconova Therapeutics' earnings last quarter?
Onconova Therapeutics, Inc. (NASDAQ:ONTX) posted its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($...
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Onconova Therapeutics's stock reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 202...
What price target have analysts set for ONTX?
3 Wall Street analysts have issued 12 month target prices for Onconova Therapeutics' shares. Their forecasts range from $7.00 to $12.00. On average...
Who are Onconova Therapeutics' key executives?
Onconova Therapeutics' management team includes the following people: Steven M. Fruchtman , President, Chief Executive Officer & Director ( Link...
Who are some of Onconova Therapeutics' key competitors?
Some companies that are related to Onconova Therapeutics include Annexon (ANNX) , scPharmaceuticals (SCPH) , BriaCell Therapeutics (BCTX) , Nex...
About Onconova Therapeutics
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E.
Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 2 buy ratings for the stock.
What is Onconova Therapeutics?
What: Shares of Onconova Therapeutics ( NASDAQ:ONTX), a clinical-stage biopharmaceutical company developing small-molecule drugs to treat cancer, dropped as much as 22% after announcing the interim results of its late-stage metastatic pancreatic cancer study .
Is Onconova discontinuing Gemzar?
So what: According to Onconova's press release, which came out after the closing bell yesterday, Onconova is discontinuing its late-stage study of intravenous rigosertib in combination with Eli Lilly 's Gemzar in treating front-line metastatic cancer.
What is Onconova Therapeutics?
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.
When is Onconova 2021?
(NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will participate in A.G.P.’s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021 . The event will consist of 1-on-1 virtual investor meetings. Investors participating in the virtual conference who are
How much was the General and Administrative expenses in 2021?
General and administrative expenses were $2.2 million for the first quarter of 2021, compared with $1.8 million for the first quarter of 2020. The increase was primarily related to higher special stockholder meeting by proxy expenses and insurance costs in the 2021 period.
How much is research and development in 2021?
Research and development expenses were $1.9 million for the first quarter of 2021, compared with $3.4 million for the first quarter of 2020. The decrease was primarily related to lower expenses for the oral rigosertib combination program and the completed Phase 3 INSPIRE study in the 2021 period.
How much cash is in the first quarter of 2021?
First Quarter Financial Results Cash and cash equivalents as of March 31, 2021 were $48.0 million, compared with $19.0 million as of December 31, 2020. The Company believes that its cash and cash equivalents will be sufficient to fund ongoing clinical trials and business operations for more than 18 months.
Is Onconova a multi-kinase inhibitor?
Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in 2Q21, and a dose-escalation and expansion Phase 1 trial is currently underway in China. Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, ...
What is ON 123300?
Phase 1 clinical trial of ON 123300, the Company's proprietary, novel multi-kinase inhibitor.
When will Onconova stock split?
Onconova Therapeutics announced a one-for-fifteen reverse stock split of its common stock, effective May 20, 2021. Beginning at the open of trading on May 21, 2021, Onconova's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis.
